FindTrial
Sign In

Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)

Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028152
Enrollment
Unknown
Registered
2019-12-13
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

Gold Standard:Clinical outcome
Index test:serum IL-6

Sponsors

Zhongda Hospital Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: participants received right heart catheterization examination and were clearly diagnosed as PAH.

Exclusion criteria

Exclusion criteria: Patients were excluded if they have heritable PAH, drugs/toxins induced PAH, idiopathic PAH or PH associated with chronic obstructive pulmonary disease (COPD), obstructive sleep apnea-hypopnea syndrome(OSAHS), chronic thromboembolic pulmonary hypertension (CTEPH), left heart disease, interstitial lung disease.

Design outcomes

Primary

MeasureTime frame
CTD-PAH;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactChengchun Tang

Medical School, Southeast University

tangchengchun@hotmail.com+86 13914705570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026